In both in vitro and in vivo generated TAMs, Fra-1 drives the differentiation toward the tumor-promoting M2d phenotype through mechanisms dependent on autocrine pathways triggered by the transactivation of the interleukin-6 promoter [37,74]. This evidence concerns the gene IL6 and neoplasm.